Certain differentially methylated CpG sites, for example, cg22982173 in HTT itself, might prove to be useful biomarkers, and the fact that some DNMT inhibitors that are FDA approved for the treatment of other ailments ameliorate some aspects of HD pathology are especially encouraging. The gene discussed is DNMT1; the disease is Huntington disease.